Skip to main content
PMC home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2009;189:203–241. doi: 10.1007/978-3-540-79086-0_8

Interferons and Their Use in Persistent Viral Infections

Stéphane Chevaliez 2, Jean-Michel Pawlotsky 2,✉
Editors: Hans-Georg Kräusslich1, Ralf Bartenschlager1
PMCID: PMC7114994  PMID: 19048202

Abstract

In 2007, the world celebrated the 50th anniversary of the discovery of interferon (IFN) by Isaacs and Lindenmann. Subsequently, the IFN-α gene was cloned, fully sequenced and IFN-α was produced in recombinant form. Recombinant IFN-α is now used as the basis for treatment of chronic hepatitis C virus infection and can also be used to treat certain forms of chronic hepatitis B virus infections. IFNs have also been used in other viral infections, although with less success. The antiviral mechanisms of IFNs are reviewed in this chapter as well as the utility of IFNs in the treatment of persistent viral infections.

Keywords: Sustained Virological Response, Sustained Virological Response Rate, Adefovir Dipivoxil, Persistent Viral Infection, Lamivudine Monotherapy

Contributor Information

Hans-Georg Kräusslich, Email: hans-georg_kraeusslich@med.uni-heidelberg.de.

Ralf Bartenschlager, Email: ralf_bartenschlager@med.uni-heidelberg.de.

Jean-Michel Pawlotsky, Email: jean-michel.pawlotsky@hmn.aphp.fr.

References

  1. (1997) National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 26:2S–10S [DOI] [PubMed]
  2. (1999) EASL International Consensus Conference on hepatitis C. Paris, 26–27 February 1999. Consensus statement. J Hepatol 31 Suppl 1:3–8 [PubMed]
  3. (2002) National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002-June 10–12, 2002. Hepatology 36:S3–S20 [DOI] [PubMed]
  4. Afdhal NH, O'Brien C, Godofsky E, Rodriguez-Torres M, Pappas SC, Pockros P, Lawitz E, Bzowej N, Rustgi V, Sulkowski M, Sherman KE, Jacobson I, Chao G, Knox S, Pietropaolo K, Brown N. Valopicitabine (NM283), alone or with peg-interferon, compared to peg-interferon/ribavirin (PEGIFN/RBV) retreatment in hepatitis C patients with prior non-response to PEGIFN/RBV: week 24 results. J Hepatol. 2006;44(2):S19. doi: 10.1016/S0168-8278(06)80040-1. [DOI] [Google Scholar]
  5. Akarca US, Ersoz G, Gunsar F, Karasu Z, Saritas E, Yuce G, Batur Y. Interferon-lamivudine combination is no better than lamivudine alone in anti-HBe-positive chronic hepatitis B. Antivir Ther. 2004;9:325–334. [PubMed] [Google Scholar]
  6. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol. 2006;80:4501–4509. doi: 10.1128/JVI.80.9.4501-4509.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bain VG, Kaita KD, Yoshida EM, Swain MG, Heathcote EJ, Neumann AU, Fiscella M, Yu R, Osborn BL, Cronin PW, Freimuth WW, McHutchison JG, Subramanian GM. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol. 2006;44:671–678. doi: 10.1016/j.jhep.2005.12.011. [DOI] [PubMed] [Google Scholar]
  8. Bain VG, Marotta P, Kaita K, Yoshida E, Swain MG, Bailey R, Neumann AU, Cronin PW, McHutchison JG, Pulkstenis E, Subramanian GM. Comparable antiviral response rates with albumin interferon alpha-2b dosed at Q2W or Q4W intervals in naive subjects with genotype 2 or 3 chronic hepatitis C. J Hepatol. 2007;46:S7. doi: 10.1016/S0168-8278(07)61607-9. [DOI] [Google Scholar]
  9. Balan V, Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, Wiesner RH, Dickson RC, Post AB, Redfield RR, Davis GL, Neumann AU, Osborn BL, Freimuth WW, Subramanian GM. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir Ther. 2006;11:35–45. [PubMed] [Google Scholar]
  10. Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, Pellicelli A, Grisorio B, Barbarini G. Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Scand J Gastroenterol. 1999;34:928–933. doi: 10.1080/003655299750025426. [DOI] [PubMed] [Google Scholar]
  11. Barbaro G, Zechini F, Pellicelli AM, Francavilla R, Scotto G, Bacca D, Bruno M, Babudieri S, Annese M, Matarazzo F, Di Stefano G, Barbarini G. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J Hepatol. 2001;35:406–411. doi: 10.1016/S0168-8278(01)00145-3. [DOI] [PubMed] [Google Scholar]
  12. Blatt LM, Davis JM, Klein SB, Taylor MW. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res. 1996;16:489–499. doi: 10.1089/jir.1996.16.489. [DOI] [PubMed] [Google Scholar]
  13. Bocher WO, Schuchmann M, Link R, Hillenbrand H, Rahman F, Sprinzl M, Mudter J, Lohr HF, Galle PR. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy. Liver Int. 2006;26:319–325. doi: 10.1111/j.1478-3231.2005.01239.x. [DOI] [PubMed] [Google Scholar]
  14. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol. 1997;15:749–795. doi: 10.1146/annurev.immunol.15.1.749. [DOI] [PubMed] [Google Scholar]
  15. Bortolotti F, Jara P, Barbera C, Gregorio GV, Vegnente A, Zancan L, Hierro L, Crivellaro C, Vergani GM, Iorio R, Pace M, Con P, Gatta A. Long term effect of alpha interferon in children with chronic hepatitis B. Gut. 2000;46:715–718. doi: 10.1136/gut.46.5.715. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, Miglioli M, Barbara L. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology. 1994;107:812–817. doi: 10.1016/0016-5085(94)90131-7. [DOI] [PubMed] [Google Scholar]
  17. Brockmeyer NH, Poffhoff A, Bader A, Hochdorfer B, Schlottmann R, Rasokat H, Altmeyer P, Kreuter A. Treatment of condylomata acuminata with pegylated interferon alfa-2b in HIV-infected patients. Eur J Med Res. 2006;11:27–32. [PubMed] [Google Scholar]
  18. Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, Bourlère M, Renou C, Tran A, Melin P, Hézode C, Chevallier M, Bouvier-Alias M, Chevaliez S, Montestruc F, Lonjon-Domanec I, Pawlotsky JM. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2a plus ribavirin combination. Gastroenterology. 2006;131:1339–1341. doi: 10.1053/j.gastro.2006.07.022. [DOI] [PubMed] [Google Scholar]
  19. Buckwold VE, Wei J, Huang Z, Huang C, Nalca A, Wells J, Russell J, Collins B, Ptak R, Lang W, Scribner C, Blanchett D, Alessi T, Langecker P. Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses. Antiviral Res. 2007;73:118–125. doi: 10.1016/j.antiviral.2006.08.005. [DOI] [PubMed] [Google Scholar]
  20. Calleri G, Cariti CaritiG, Gaiottino F, De Rosa FG, Bargiacchi O, Audagnotto S, Quaglia S, De Blasi T, Romano P, Traverso A, Leo G, Carbone R, Del Mastro B, Tinelli M, Caramello P, Perri G. A short course of pegylated interferon-alpha in acute HCV hepatitis. J Viral Hepat. 2007;14:116–121. doi: 10.1111/j.1365-2893.2006.00802.x. [DOI] [PubMed] [Google Scholar]
  21. Canbakan B, Senturk H, Tabak F, Akdogan M, Tahan V, Mert A, Sut N, Ozaras R, Midilli K, Ozbay G. Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis: a randomized trial. J Gastroenterol Hep-atol. 2006;21:657–663. doi: 10.1111/j.1440-1746.2006.04082.x. [DOI] [PubMed] [Google Scholar]
  22. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet. 1989;2:588–591. doi: 10.1016/S0140-6736(89)90713-7. [DOI] [PubMed] [Google Scholar]
  23. Carreno V, Marcellin P, Hadziyannis S, Salmeron J, Diago M, Kitis GE, Vafiadis I, Schalm SW, Zahm F, Manzarbeitia F, Jimenez FJ, Quiroga JA. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. Hepatology. 1999;30:277–282. doi: 10.1002/hep.510300117. [DOI] [PubMed] [Google Scholar]
  24. Castelnau C, Le Gal F, Ripault MP, Gordien E, Martinot-Peignoux M, Boyer N, Pham BN, Maylin S, Bedossa P, Deny P, Marcellin P, Gault E. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology. 2006;44:728–735. doi: 10.1002/hep.21325. [DOI] [PubMed] [Google Scholar]
  25. Castro A, Suarez D, Inglada L, Carballo E, Dominguez A, Diago M, Such J, Del Olmo JA, Perez-Mota A, Pedreira J, Quiroga JA, Carreno V. Multicenter randomized, controlled study of intramuscular administration of interferon-beta for the treatment of chronic hepatitis C. J Interferon Cytokine Res. 1997;17:27–30. doi: 10.1089/jir.1997.17.27. [DOI] [PubMed] [Google Scholar]
  26. Chan HL, Hui AY, Wong VW, Chim AM, Wong ML, Sung JJ. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology. 2005a;41:1357–1364. doi: 10.1002/hep.20695. [DOI] [PubMed] [Google Scholar]
  27. Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, Chan FK, Hung LC, Lee YT, Tam JS, Lam CW, Sung JJ. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med. 2005b;142:240–250. doi: 10.7326/0003-4819-142-4-200502150-00006. [DOI] [PubMed] [Google Scholar]
  28. Chang CC, Chen TT, Cox BW, Dawes GN, Stemmer WP, Punnonen J, Patten PA. Evolution of a cytokine using DNA family shuffling. Nat Biotechnol. 1999;17:793–797. doi: 10.1038/70147. [DOI] [PubMed] [Google Scholar]
  29. Chen J, Baig E, Fish EN. Diversity and relatedness among the type I interferons. J Interferon Cytokine Res. 2004;24:687–698. doi: 10.1089/jir.2004.24.687. [DOI] [PubMed] [Google Scholar]
  30. Clemens MJ. Interferons and apoptosis. J Interferon Cytokine Res. 2003;23:277–292. doi: 10.1089/107999003766628124. [DOI] [PubMed] [Google Scholar]
  31. Coccia EM, Krust B, Hovanessian AG. Specific inhibition of viral protein synthesis in HIV-infected cells in response to interferon treatment. J Biol Chem. 1994;269:23087–23094. [PubMed] [Google Scholar]
  32. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, Chutaputti A, Chang WY, Zahm FE, Pluck N. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 2003;10:298–305. doi: 10.1046/j.1365-2893.2003.00450.x. [DOI] [PubMed] [Google Scholar]
  33. Creagh EM, O'Neill LA. TLRs, NLRs and RLRs: a trinity of pathogen sensors that cooperate in innate immunity. Trends Immunol. 2006;27:352–357. doi: 10.1016/j.it.2006.06.003. [DOI] [PubMed] [Google Scholar]
  34. Dash S, Prabhu R, Hazari S, Bastian F, Garry R, Zou W, Haque S, Joshi V, Regenstein FG, Thung SN. Interferons alpha, beta, gamma each inhibit hepatitis C virus replication at the level of internal ribosome entry site-mediated translation. Liver Int. 2005;25:580–594. doi: 10.1111/j.1478-3231.2005.01082.x. [DOI] [PubMed] [Google Scholar]
  35. de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, Mele A, Paumgartner G, Pietrangelo A, Rodes J, Rosenberg W, Valla D. EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version) J Hepatol. 2003;39(1):S3–S25. doi: 10.1016/S0168-8278(03)00213-7. [DOI] [PubMed] [Google Scholar]
  36. De Rosa FG, Bargiacchi O, Audagnotto S, Garazzino S, Cariti G, Veronese L, Raiteri R, Calleri G, Di Perri G. The early HCV RNA dynamics in patients with acute hepatitis C treated with pegylated interferon-alpha2b. Antivir Ther. 2006;11:165–171. [PubMed] [Google Scholar]
  37. Di Bisceglie A (1997) Hepatitis D virus. Marcel Dekker, NY
  38. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology. 2002;36:S121–S127. doi: 10.1053/jhep.2002.36228. [DOI] [PubMed] [Google Scholar]
  39. Dooley JS, Davis GL, Peters M, Waggoner JG, Goodman Z, Hoofnagle JH. Pilot study of recombinant human alpha-interferon for chronic type B hepatitis. Gastroenterology. 1986;90:150–157. doi: 10.1016/0016-5085(86)90087-9. [DOI] [PubMed] [Google Scholar]
  40. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, Yao L, Liu H, Barahmand-pour F, Sivakumar P, Chan C, Birks C, Foster D, Clegg CH, Wietzke-Braun P, Mihm S, Klucher KM. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology. 2006;44:896–906. doi: 10.1002/hep.21312. [DOI] [PubMed] [Google Scholar]
  41. Dumoutier L, Lejeune D, Hor S, Fickenscher H, Renauld JC. Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3. Biochem J. 2003;370:391–396. doi: 10.1042/BJ20021935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem. 2004;279:32269–32274. doi: 10.1074/jbc.M404789200. [DOI] [PubMed] [Google Scholar]
  43. Ealick SE, Cook WJ, Vijay-Kumar S, Carson M, Nagabhushan TL, Trotta PP, Bugg CE. Three-dimensional structure of recombinant human interferon-gamma. Science. 1991;252:698–702. doi: 10.1126/science.1902591. [DOI] [PubMed] [Google Scholar]
  44. Emilie D, Burgard M, Lascoux-Combe C, Laughlin M, Krzysiek R, Pignon C, Rudent A, Molina JM, Livrozet JM, Souala F, Chene G, Grangeot-Keros L, Galanaud P, Sereni D, Rouzioux C. Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study. AIDS. 2001;15:1435–1437. doi: 10.1097/00002030-200107270-00014. [DOI] [PubMed] [Google Scholar]
  45. Enomoto M, Tamori A, Kohmoto MT, Hayashi T, Jomura H, Habu D, Sakaguchi H, Takeda T, Kawada N, Seki S, Shiomi S, Koh N, Nishiguchi S. Lamivudine and IFN-beta sequential therapy in HBe antigen-positive patients with chronic hepatitis B virus genotype C infection. J Interferon Cytokine Res. 2007;27:201–207. doi: 10.1089/jir.2006.0140. [DOI] [PubMed] [Google Scholar]
  46. Erhardt A, Gerlich W, Starke C, Wend U, Donner A, Sagir A, Heintges T, Haussinger D. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int. 2006;26:805–810. doi: 10.1111/j.1478-3231.2006.01279.x. [DOI] [PubMed] [Google Scholar]
  47. Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van Eyken P, Gibo Y, Caruso L, Scaccabarozzi S, Criscuolo D, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med. 1994;330:88–94. doi: 10.1056/NEJM199401133300202. [DOI] [PubMed] [Google Scholar]
  48. Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R, Serra G, Lai ME, Loy M, Caruso L, Desmet V, Purcell RH, Balestrieri A. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology. 2004;126:1740–1749. doi: 10.1053/j.gastro.2004.03.017. [DOI] [PubMed] [Google Scholar]
  49. Fattovich G, Giustina G, Sanche-Tapias J, Quero C, Mas A, Olivotto PG, Solinas A, Almasio P, Hadziyannis S, Degos F, de Moura MC, Krogsgaard K, Pantalena M, Realdi G, Corrocher R, Schalm SW. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol. 1998;93:896–900. doi: 10.1111/j.1572-0241.1998.00272.x. [DOI] [PubMed] [Google Scholar]
  50. Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, Schalm SW. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut. 2000;46:420–426. doi: 10.1136/gut.46.3.420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Fernande-Cruz E, Lang JM, Frissen J, Furner V, Chateauvert M, Boucher CA, Dowd P, Stevens J. Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 × 10(6)/L: results of the Zidon trial. AIDS. 1995;9:1025–1035. [PubMed] [Google Scholar]
  52. Fernie BF, Poli G, Fauci AS. Alpha interferon suppresses virion but not soluble human immunodeficiency virus antigen production in chronically infected T-lymphocytic cells. J Virol. 1991;65:3968–3971. doi: 10.1128/jvi.65.7.3968-3971.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Fischl MA, Richman DD, Saag M, Meng TC, Squires KE, Holde-Wiltse J, Meehan PM. Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:247–253. doi: 10.1097/00042560-199712010-00005. [DOI] [PubMed] [Google Scholar]
  54. Flink HJ, Hansen BE, Heathcote EJ, Feinman SV, Simsek H, Karayalcin S, Mach T, Leemans WF, de Man RA, Verhey E, Schalm SW, Janssen HL. Successful treatment with peginter-feron alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine. Am J Gastroenterol. 2006a;101:2523–2529. doi: 10.1111/j.1572-0241.2006.00418.x. [DOI] [PubMed] [Google Scholar]
  55. Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol. 2006b;101:297–303. doi: 10.1111/j.1572-0241.2006.00418.x. [DOI] [PubMed] [Google Scholar]
  56. Frese M, Schwarzle V, Barth K, Krieger N, Lohmann V, Mihm S, Haller O, Bartenschlager R. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology. 2002;35:694–703. doi: 10.1053/jhep.2002.31770. [DOI] [PubMed] [Google Scholar]
  57. Fried M, Jensen D, Rodrigue -Torres M, Nyberg L, Di Bisceglie A, Morgan T, Pockros PJ, Lin A, Cupelli L, Nelson D. Improved sustained virological response (SVR) rates with higher, fixed doses of peginterferon alfa-2a (40 kD) (Pegasys) plus ribavirin (RBV) (Copegus) in patients with “difficult-to-treat” characteristics. Hepatology. 2006;44(1):314A. [Google Scholar]
  58. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982. doi: 10.1056/NEJMoa020047. [DOI] [PubMed] [Google Scholar]
  59. Gack MU, Shin YC, Joo CH, Urano T, Liang C, Sun L, Takeuchi O, Akira S, Chen Z, Inoue S, Jung JU. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature. 2007;446:916–920. doi: 10.1038/nature05732. [DOI] [PubMed] [Google Scholar]
  60. Gaeta GB, Stroffolini T, Chiaramonte M, Ascione T, Stornaiuolo G, Lobello S, Sagnelli E, Brunetto MR, Rizzetto M. Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology. 2000;32:824–827. doi: 10.1053/jhep.2000.17711. [DOI] [PubMed] [Google Scholar]
  61. Gale M, Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature. 2005;436:939–945. doi: 10.1038/nature04078. [DOI] [PubMed] [Google Scholar]
  62. Garripoli A, Di Marco V, Cozzolongo R, Costa C, Smedile A, Fabiano A, Bonino F, Rizzetto M, Verme G, Craxi A, et al. Ribavirin treatment for chronic hepatitis D: a pilot study. Liver. 1994;14:154–157. doi: 10.1111/j.1600-0676.1994.tb00065.x. [DOI] [PubMed] [Google Scholar]
  63. Gattoni A, Parlato A, Vangieri B, Bresciani M, Derna R. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts) Clin Ter. 2006a;157:377–386. [PubMed] [Google Scholar]
  64. Gattoni A, Parlato A, Vangieri B, Bresciani M, Derna R. Interferon-gamma: biologic functions and HCV therapy (type I/II) (2 of 2 parts) Clin Ter. 2006b;157:457–468. [PubMed] [Google Scholar]
  65. Gaudin JL, Faure P, Godinot H, Gerard F, Trepo C. The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial. Liver. 1995;15:45–52. doi: 10.1111/j.1600-0676.1995.tb00106.x. [DOI] [PubMed] [Google Scholar]
  66. Gendelman HE, Baca LM, Turpin J, Kalter DC, Hansen B, Orenstein JM, Dieffenbach CW, Friedman RM, Meltzer MS. Regulation of HIV replication in infected monocytes by IFN-alpha. Mechanisms for viral restriction. J Immunol. 1990;145:2669–26676. [PubMed] [Google Scholar]
  67. Giovannini M, Zuccotti GV, Biasucci G, Locatelli V, Riva E. Combined zidovudine and interferon-alpha 2a therapy in children with acquired immune deficiency syndrome. J Int Med Res. 1992;20:295–301. doi: 10.1177/030006059202000312. [DOI] [PubMed] [Google Scholar]
  68. Gorbakov VV, Kim H, Oronsky B, Lang W. HCV RNA results from a Phase II, randomized, open-labeled study of omega interferon (IFN) with or without ribavirin in IFN-naive genotype 1 chronic HCV patients. Hepatology. 2005;42:705A. [Google Scholar]
  69. Gough DJ, Sabapathy K, Ko EY, Arthur HA, Schreiber RD, Trapani JA, Clarke CJ, Johnstone RW. A novel c-Jun-dependent signal transduction pathway necessary for the transcriptional activation of interferon gamma response genes. J Biol Chem. 2007;282:938–946. doi: 10.1074/jbc.M607674200. [DOI] [PubMed] [Google Scholar]
  70. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol. 2001;19:65–91. doi: 10.1146/annurev.immunol.19.1.65. [DOI] [PubMed] [Google Scholar]
  71. Gunsar F, Akarca US, Ersoz G, Kobak AC, Karasu Z, Yuce G, Ilter T, Batur Y. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther. 2005;10:721–726. [PubMed] [Google Scholar]
  72. Habersetzer F, Boyer N, Marcellin P, Bailly F, Ahmed SN, Alam J, Benhamou JP, Trepo C. A pilot study of recombinant interferon beta-1a for the treatment of chronic hepatitis C. Liver. 2000;20:437–441. doi: 10.1034/j.1600-0676.2000.020006437.x. [DOI] [PubMed] [Google Scholar]
  73. Hadziyannis SJ, Sette H, Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355. doi: 10.7326/0003-4819-140-5-200403020-00010. [DOI] [PubMed] [Google Scholar]
  74. Hansen BD, Nara PL, Maheshwari RK, Sidhu GS, Bernbaum JG, Hoekzema D, Meltzer MS, Gendelman HE. Loss of infectivity by progeny virus from alpha interferon-treated human immunodeficiency virus type 1-infected T cells is associated with defective assembly of envelope gp120. J Virol. 1992;66:7543–7548. doi: 10.1128/jvi.66.12.7543-7548.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Hayden MS, West AP, Ghosh S. NF-kappaB and the immune response. Oncogene. 2006;25:6758–6780. doi: 10.1038/sj.onc.1209943. [DOI] [PubMed] [Google Scholar]
  76. Hezode C, Bouvie-Alias M, Roudo-Thoraval F, Zafrani S, Dhumeaux D, Mallat A, Pawlotsky JM. Efficacy and safety of peginterferon alpha-2a administrated every five days in combination with ribavirin in HCV genotype 1-infected patients with severe fibrosis not responding to weekly administrations of peginterferon in combination with ribavirin. Hepatology. 2006;44:322A. [Google Scholar]
  77. Ho DD, Hartshorn KL, Rota TR, Andrews CA, Kaplan JC, Schooley RT, Hirsch MS. Re-combinant human interferon alfa-A suppresses HTLV-III replication in vitro. Lancet. 1985;1:602–604. doi: 10.1016/S0140-6736(85)92144-0. [DOI] [PubMed] [Google Scholar]
  78. Hodson EM, Jones CA, Strippoli GF, Webster AC, Craig JC (2007) Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev CD005129 [DOI] [PubMed]
  79. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, Shimada N, Ohba Y, Takaoka A, Yoshida N, Taniguchi T. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature. 2005;434:772–777. doi: 10.1038/nature03464. [DOI] [PubMed] [Google Scholar]
  80. Hong SH, Cho O, Kim K, Shin HJ, Kotenko SV, Park S. Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res. 2007;126:245–249. doi: 10.1016/j.virusres.2007.03.006. [DOI] [PubMed] [Google Scholar]
  81. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, Jones EA. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986;315:1575–1578. doi: 10.1056/NEJM198612183152503. [DOI] [PubMed] [Google Scholar]
  82. Horiike N, Onji M. Combination therapy with interferon-alpha and ribavirin as im-munomodulators in patients with chronic hepatitis C. J Gastroenterol. 2003;38:302–304. doi: 10.1007/s005350300054. [DOI] [PubMed] [Google Scholar]
  83. Hui CK, Lai LS, Lam P, Zhang HY, Fung TT, Lai ST, Wong WM, Lo CM, Fan ST, Leung N, Lau GK. 48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection. Aliment Pharmacol Ther. 2006;23:1171–1178. doi: 10.1111/j.1365-2036.2006.02887.x. [DOI] [PubMed] [Google Scholar]
  84. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci. 1957;147:258–267. [PubMed] [Google Scholar]
  85. Isomura S, Ichikawa T, Miyazu M, Naruse H, Shibata M, Imanishi J, Matsuo A, Kishida T, Karaki T. The preventive effect of human interferon-alpha on influenza infection; modification of clinical manifestations of influenza in children in a closed community. Biken J. 1982;25:131–137. [PubMed] [Google Scholar]
  86. Jacobson IM, Brown RS, Freilich B, Afdhal N, Kwo P, Santoro J, Becker S, Wakil A, Pound D, Godofsky E, Staruss R, Bernstein D, Flamm S, Bala N, Araya V, Davis M, Monsour H, Vierling J, Regenstein F, Balan V, Dragutsky M, Epstein M, Herring RW, Rubin R, Galler G, Pauly MP, Griffel LH, Brass CA. Weight-based ribavirin dosing (WBD) increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): final results of the WIN-R study, a US community-based trial. Hepatology. 2005;42(1):749A. [Google Scholar]
  87. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, Manns MP. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001;345:1452–1457. doi: 10.1056/NEJMoa011232. [DOI] [PubMed] [Google Scholar]
  88. Jang MK, Chung YH, Choi MH, Kim JA, Ryu SH, Shin JW, Kim IS, Park NH, Lee HC, Lee YS, Suh DJ. Combination of alpha-interferon with lamivudine reduces viral breakthrough during long-term therapy. J Gastroenterol Hepatol. 2004;19:1363–1368. doi: 10.1111/j.1440-1746.2004.03464.x. [DOI] [PubMed] [Google Scholar]
  89. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW. Pegylated in-terferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365:123–129. doi: 10.1016/S0140-6736(05)17701-0. [DOI] [PubMed] [Google Scholar]
  90. Jen J, Laughlin M, Chung C, Heft S, Affrime MB, Gupta SK, Glue P, Hajian G. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther. 2002;72:349–361. doi: 10.1067/mcp.2002.127112. [DOI] [PubMed] [Google Scholar]
  91. Jen JF, Glue P, Gupta S, Zambas D, Hajian G. Population pharmacokinetic and pharmacody-namic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit. 2000;22:555–565. doi: 10.1097/00007691-200010000-00010. [DOI] [PubMed] [Google Scholar]
  92. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006;43:954–960. doi: 10.1002/hep.21159. [DOI] [PubMed] [Google Scholar]
  93. Kagawa T, Morizane T, Saito H, Tsunematsu S, Tada S, Kumagai N, Tsuchimoto K, Sugiura H, Mukai M, Tsuchiya M. A pilot study of long-term weekly interferon-beta administration for chronic hepatitis B. Am J Gastroenterol. 1993;88:212–216. [PubMed] [Google Scholar]
  94. Kalil AC, Devetten MP, Singh S, Lesiak B, Poage DP, Bargenquast K, Fayad P, Freifeld AG. Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases. Clin Infect Dis. 2005;40:764–766. doi: 10.1086/427945. [DOI] [PubMed] [Google Scholar]
  95. Kato H, Sato S, Yoneyama M, Yamamoto M, Uematsu S, Matsui K, Tsujimura T, Takeda K, Fujita T, Takeuchi O, Akira S. Cell type-specific involvement of RIG-I in antiviral response. Immunity. 2005;23:19–28. doi: 10.1016/j.immuni.2005.04.010. [DOI] [PubMed] [Google Scholar]
  96. Kaymakoglu S, Karaca C, Demir K, Poturoglu S, Danalioglu A, Badur S, Bozaci M, Besisik F, Cakaloglu Y, Okten A. Alpha interferon and ribavirin combination therapy of chronic hepatitis D. Antimicrob Agents Chemother. 2005;49:1135–1138. doi: 10.1128/AAC.49.3.1135-1138.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Kaymakoglu S, Danalioglu A, Demir K, Karaca C, Akyuz F, Onel D, Badur S, Cevikbas U, Besisik F, Cakaloglu Y, Okten A. Long-term results of interferon alpha monotherapy in patients with HBeAg-negative chronic hepatitis B. Dig Dis Sci. 2007a;52:727–731. doi: 10.1007/s10620-006-9445-1. [DOI] [PubMed] [Google Scholar]
  98. Kaymakoglu S, Oguz D, Gur G, Gurel S, Tankurt E, Ersoz G, Ozenirler S, Kalayci C, Poturoglu S, Cakaloglu Y, Okten A. Pegylated interferon alfa-2b monotherapy and pegylated interferon alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B. Antimicrob Agents Chemother. 2007b;51:3020–3022. doi: 10.1128/AAC.00088-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Keeffe EB, Hollinger FB. Therapy of hepatitis C: consensus interferon trials. Hepatology. 1997;26:101S–107S. doi: 10.1002/hep.510260718. [DOI] [PubMed] [Google Scholar]
  100. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H, Wright TL. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol. 2006;4:936–962. doi: 10.1016/j.cgh.2006.05.016. [DOI] [PubMed] [Google Scholar]
  101. Kim KI, Sasase N, Taniguchi M, Mita K, Kinoshita K, Togitani T, Shikata M, Kimura N, Izawa S, Ohtani A, Nakao K, Muramoto Y, Kim SR, Nabeshima S, Ishii F, Tanaka K, Hayashi Y. Interferon-beta induction/interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. Int J Clin Pharmacol Res. 2005;25:71–76. [PubMed] [Google Scholar]
  102. Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs. 2001;15:419–429. doi: 10.2165/00063030-200115070-00001. [DOI] [PubMed] [Google Scholar]
  103. Krown SE, Aeppli D, Balfour HH Jr. Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:245–254. doi: 10.1097/00042560-199903010-00005. [DOI] [PubMed] [Google Scholar]
  104. LaFleur DW, Nardelli B, Tsareva T, Mather D, Feng P, Semenuk M, Taylor K, Buergin M, Chinchilla D, Roshke V, Chen G, Ruben SM, Pitha PM, Coleman TA, Moore PA. Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J Biol Chem. 2001;276:39765–39771. doi: 10.1074/jbc.M102502200. [DOI] [PubMed] [Google Scholar]
  105. Lampertico P, Del Ninno E, Manzin A, Donato MF, Rumi MG, Lunghi G, Morabito A, Clementi M, Colombo M. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology. 1997;26:1621–1625. doi: 10.1002/hep.510260634. [DOI] [PubMed] [Google Scholar]
  106. Lampertico P, Del Ninno E, Vigano M, Romeo R, Donato MF, Sablon E, Morabito A, Colombo M. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology. 2003;37:756–763. doi: 10.1053/jhep.2003.50148. [DOI] [PubMed] [Google Scholar]
  107. Lane HC. Interferons in HIV and related diseases. AIDS. 1994;8(3):S19–S23. doi: 10.1097/00002030-199409001-00005. [DOI] [PubMed] [Google Scholar]
  108. Lanford RE, Guerra B, Lee H, Averett DR, Pfeiffer B, Chavez D, Notvall L, Bigger C. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic repli-cons. J Virol. 2003;77:1092–1104. doi: 10.1128/JVI.77.2.1092-1104.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Lau DT, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology. 1997;113:1660–1667. doi: 10.1053/gast.1997.v113.pm9352870. [DOI] [PubMed] [Google Scholar]
  110. Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology. 1998;28:1121–1127. doi: 10.1002/hep.510280430. [DOI] [PubMed] [Google Scholar]
  111. Lau DT, Doo E, Park Y, Kleiner DE, Schmid P, Kuhns MC, Hoofnagle JH. Lamivudine for chronic delta hepatitis. Hepatology. 1999a;30:546–549. doi: 10.1002/hep.510300217. [DOI] [PubMed] [Google Scholar]
  112. Lau DT, Kleiner DE, Park Y, Di Bisceglie AM, Hoofnagle JH. Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology. 1999b;117:1229–1233. doi: 10.1016/S0016-5085(99)70409-9. [DOI] [PubMed] [Google Scholar]
  113. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682–2695. doi: 10.1056/NEJMoa043470. [DOI] [PubMed] [Google Scholar]
  114. Leemans WF, Flink HJ, Janssen HL, Niesters HG, Schalm SW, de Man RA. The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection. J Hepatol. 2006;44:507–511. doi: 10.1016/j.jhep.2005.12.004. [DOI] [PubMed] [Google Scholar]
  115. Lewis M, Amsden JR. Successful treatment of West Nile virus infection after approximately 3 weeks into the disease course. Pharmacotherapy. 2007;27:455–458. doi: 10.1592/phco.27.3.455. [DOI] [PubMed] [Google Scholar]
  116. Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, Gane E, Kao JH, Omata M. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int. 2005;25:472–489. doi: 10.1111/j.1478-3231.2005.01134.x. [DOI] [PubMed] [Google Scholar]
  117. Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, Liaw YF. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol. 2007;46:45–52. doi: 10.1016/j.jhep.2006.08.021. [DOI] [PubMed] [Google Scholar]
  118. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology. 2005;41:275–279. doi: 10.1002/hep.20563. [DOI] [PubMed] [Google Scholar]
  119. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34:395–403. doi: 10.1053/jhep.2001.26371. [DOI] [PubMed] [Google Scholar]
  120. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–539. doi: 10.1002/hep.21513. [DOI] [PubMed] [Google Scholar]
  121. Lok AS, Chung HT, Liu VW, Ma OC. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology. 1993;105:1833–1838. doi: 10.1016/0016-5085(93)91082-s. [DOI] [PubMed] [Google Scholar]
  122. Madejon A, Cotonat T, Bartolome J, Castillo I, Carreno V. Treatment of chronic hepatitis D virus infection with low and high doses of interferon-alpha 2a: utility of polymerase chain reaction in monitoring antiviral response. Hepatology. 1994;19:1331–1336. [PubMed] [Google Scholar]
  123. Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology. 2001;121:101–109. doi: 10.1053/gast.2001.25524. [DOI] [PubMed] [Google Scholar]
  124. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with in-terferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965. doi: 10.1016/S0140-6736(01)06102-5. [DOI] [PubMed] [Google Scholar]
  125. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351:1206–1217. doi: 10.1056/NEJMoa040431. [DOI] [PubMed] [Google Scholar]
  126. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, Rice CM. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006;131:1887–1898. doi: 10.1053/j.gastro.2006.09.052. [DOI] [PubMed] [Google Scholar]
  127. Martal JL, Chene NM, Huynh LP, L'Haridon RM, Reinaud PB, Guillomot MW, Charlier MA, Charpigny SY. IFN-tau: a novel subtype I IFN1. Structural characteristics, non-ubiquitous expression, structure-function relationships, a pregnancy hormonal embryonic signal and cross-species therapeutic potentialities. Biochimie. 1998;80:755–777. doi: 10.1016/S0300-9084(99)80029-7. [DOI] [PubMed] [Google Scholar]
  128. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485–1492. doi: 10.1056/NEJM199811193392101. [DOI] [PubMed] [Google Scholar]
  129. McHutchison JG, Shiffman ML, Gordon SC, Lindsay KL, Morgan T, Norkrans G, Esteban-Mur R, Poynard T, Pockros PJ, Albrecht JK, Brass C. Sustained virologic response (SVR) to interferon-alpha-2b+/− ribavirin therapy at 6 months reliably predicts long-term clearance of HCV at 5-year follow-up. J Hepatol. 2006;44(2):S275. doi: 10.1016/S0168-8278(06)80745-2. [DOI] [Google Scholar]
  130. McHutchison JG, Everson GT, Gordon S, Jacobson I, Kauffman R, McNair L, Muir AJ. Results of an interim analysis of a Phase II study of telaprevir (VX-950) with peginterferon alfa-2a and ribavirin in previously untreated subjects with hepatitis C. J Hepatol. 2007a;46:S296. doi: 10.1016/S0168-8278(07)62384-8. [DOI] [Google Scholar]
  131. McHutchison JG, Manns MP, Brown RS, Jr, Reddy KR, Shiffman ML, Wong JB. Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol. 2007b;102:880–889. doi: 10.1111/j.1572-0241.2007.01139.x. [DOI] [PubMed] [Google Scholar]
  132. Miglioresi L, Bacosi M, Russo F, Patrizi F, Saccenti P, Ursitti A, Angelis AD, Ricci GL. Consensus interferon versus interferon-alpha 2b plus ribavirin in patients with relapsing HCV infection. Hepatol Res. 2003;27:253–259. doi: 10.1016/S1386-6346(03)00269-9. [DOI] [PubMed] [Google Scholar]
  133. Montalto G, Tripi S, Cartabellotta A, Fulco M, Soresi M, Di Gaetano G, Carroccio A, Levrero M. Intravenous natural beta-interferon in white patients with chronic hepatitis C who are nonresponders to alpha-interferon. Am J Gastroenterol. 1998;93:950–953. doi: 10.1111/j.1572-0241.1998.00285.x. [DOI] [PubMed] [Google Scholar]
  134. Moskovitz DN, Manoharan P, Heathcote EJ. High dose consensus interferon in nonrespon-ders to interferon alpha-2b and ribavirin with chronic hepatitis C. Can J Gastroenterol. 2003;17:479–482. doi: 10.1155/2003/131943. [DOI] [PubMed] [Google Scholar]
  135. Munoz R, Castellano G, Fernandez I, Alvarez MV, Manzano ML, Marcos MS, Cuenca B, Solis-Herruzo JA. A pilot study of beta-interferon for treatment of patients with chronic hepatitis B who failed to respond to alpha-interferon. J Hepatol. 2002;37:655–659. doi: 10.1016/S0168-8278(02)00261-1. [DOI] [PubMed] [Google Scholar]
  136. Nagata S, Taira H, Hall A, Johnsrud L, Streuli M, Ecsodi J, Boll W, Cantell K, Weissmann C. Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature. 1980;284:316–320. doi: 10.1038/284316a0. [DOI] [PubMed] [Google Scholar]
  137. Nakajima H, Shimomura H, Iwasaki Y, Ikeda F, Umeoka F, Chengyu P, Taniguchi H, Ohnishi Y, Takagi SJ, Fujioka S, Shiratori Y. Anti-viral actions and viral dynamics in the early phase of three different regimens of interferon treatment for chronic hepatitis C: differences between the twice-daily administration of interferon-beta treatment and the combination therapy with interferon-alpha plus ribavirin. Acta Med Okayama. 2003;57:217–225. doi: 10.18926/AMO/32825. [DOI] [PubMed] [Google Scholar]
  138. Neumann A, Polis M, Rozenberg L, Jackson J, Reitano K, McLaughlin M, Koratich C, Dewar R, Masur H, Haagmans B, Kottilil S. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients. AIDS. 2007;21:1855–1865. doi: 10.1097/QAD.0b013e32825eaba7. [DOI] [PubMed] [Google Scholar]
  139. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996;334:1422–1427. doi: 10.1056/NEJM199605303342202. [DOI] [PubMed] [Google Scholar]
  140. Niro GA, Ciancio A, Tillman HL, Lagget M, Olivero A, Perri F, Fontana R, Little N, Campbell F, Smedile A, Manns MP, Andriulli A, Rizzetto M. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther. 2005a;22:227–232. doi: 10.1111/j.1365-2036.2005.02542.x. [DOI] [PubMed] [Google Scholar]
  141. Niro GA, Rosina F, Rizzetto M. Treatment of hepatitis D. J Viral Hepat. 2005b;12:2–9. doi: 10.1111/j.1365-2893.2005.00601.x. [DOI] [PubMed] [Google Scholar]
  142. Niro GA, Ciancio A, Gaeta GB, Smedile A, Marrone A, Olivero A, Stanzione M, David E, Bran-caccio G, Fontana R, Perri F, Andriulli A, Rizzetto M. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology. 2006;44:713–720. doi: 10.1002/hep.21296. [DOI] [PubMed] [Google Scholar]
  143. Novozhenov V, Zakharova N, Vinogradova E, Nikitin I, Gorbakov VV, Yakovlev A, Pak S, Rafalski V, Bogomolov P, Alessi T, Blanchett D, Lang W, Langecker P, McNally J, McHutchison JG. Phase 2 study of omega interferon alone or in combination with ribavirin in subjects with chronic hepatitis C genotype-1 infection. J Hepatol. 2007;46:S8. doi: 10.1016/S0168-8278(07)61609-2. [DOI] [Google Scholar]
  144. Onoguchi K, Yoneyama M, Takemura A, Akira S, Taniguchi T, Namiki H, Fujita T. Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem. 2007;282:7576–7581. doi: 10.1074/jbc.M608618200. [DOI] [PubMed] [Google Scholar]
  145. Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A, Moody G, Zaritskaya LS, Sung C. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther. 2002;303:540–548. doi: 10.1124/jpet.102.037002. [DOI] [PubMed] [Google Scholar]
  146. Ozes ON, Reiter Z, Klein S, Blatt LM, Taylor MW. A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities. J Interferon Res. 1992;12:55–59. doi: 10.1089/jir.1992.12.55. [DOI] [PubMed] [Google Scholar]
  147. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2001;34:306–313. doi: 10.1016/S0168-8278(00)00094-5. [DOI] [PubMed] [Google Scholar]
  148. Parvez MK, Sehgal D, Sarin SK, Basir SF, Jameel S. Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-gamma. World J Gastroenterol. 2006;12:3006–3014. doi: 10.3748/wjg.v12.i19.3006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  149. Pastore G, Santantonio T, Milella M, Monno L, Mariano N, Moschetta R, Pollice L. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. J Hepatol. 1992;14:221–225. doi: 10.1016/0168-8278(92)90161-H. [DOI] [PubMed] [Google Scholar]
  150. Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication. Hepatology. 2006;43:S207–S220. doi: 10.1002/hep.21064. [DOI] [PubMed] [Google Scholar]
  151. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology. 2007;132:1979–1998. doi: 10.1053/j.gastro.2007.03.116. [DOI] [PubMed] [Google Scholar]
  152. Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G, Lonjon I, Castera L, Dhumeaux D. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology. 2004;126:703–714. doi: 10.1053/j.gastro.2003.12.002. [DOI] [PubMed] [Google Scholar]
  153. Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, David M. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature. 2007;449:919–922. doi: 10.1038/nature06205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  154. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annu Rev Biochem. 1987;56:727–777. doi: 10.1146/annurev.bi.56.070187.003455. [DOI] [PubMed] [Google Scholar]
  155. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004;202:8–32. doi: 10.1111/j.0105-2896.2004.00204.x. [DOI] [PubMed] [Google Scholar]
  156. Peters M, Walling DM, Kelly K, Davis GL, Waggoner JG, Hoofnagle JH. Immunologic effects of interferon-alpha in man: treatment with human recombinant interferon-alpha suppresses in vitro immunoglobulin production in patients with chronic type B hepatitis. J Immunol. 1986;137:3147–3152. [PubMed] [Google Scholar]
  157. Phillpotts RJ, Higgins PG, Willman JS, Tyrrell DA, Freestone DS, Shepherd WM. Intranasal lymphoblastoid interferon (“Wellferon”) prophylaxis against rhinovirus and influenza virus in volunteers. J Interferon Res. 1984;4:535–541. doi: 10.1089/jir.1984.4.535. [DOI] [PubMed] [Google Scholar]
  158. Plauth MM, Meisel H, Langecker P, Moran M, Lang W, Blanchett D, Jetschmann JU, Brack J, von Wussow P (2002) Open-labeled study of omega interferon in previously untreated HCV-infected patients. In: Proceedings of the 37th annual meeting EASL
  159. Poli G, Orenstein JM, Kinter A, Folks TM, Fauci AS. Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. Science. 1989;244:575–577. doi: 10.1126/science.2470148. [DOI] [PubMed] [Google Scholar]
  160. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998;352:1426–1432. doi: 10.1016/S0140-6736(98)07124-4. [DOI] [PubMed] [Google Scholar]
  161. Rahal JJ, Anderson J, Rosenberg C, Reagan T, Thompson LL. Effect of interferon-alpha2b therapy on St. Louis viral meningoencephalitis: clinical and laboratory results of a pilot study. J Infect Dis. 2004;190:1084–1087. doi: 10.1086/423325. [DOI] [PubMed] [Google Scholar]
  162. Rodriguez-Torres M, Lawitz E, Muir AJ, Keane J, Kieffer TL, McNair L, McHutchison JG. Current status of subjects receiving peginterferon alfa-2a (PEG-IFN) and ribavirin (RBV) follow-on therapy after 28-day treatment with the hepatitis C protease inhibitor telaprevir (VX-950), PEG-IFN and RBV. Hepatology. 2006;44(2):532A. [Google Scholar]
  163. Rosina F, Pintus C, Meschievitz C, Rizzetto M. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology. 1991;13:1052–1056. doi: 10.1002/hep.1840130608. [DOI] [PubMed] [Google Scholar]
  164. Sainz B, Jr, Mossel EC, Peters CJ, Garry RF. Interferon-beta and interferon-gamma syner-gistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) Virology. 2004;329:11–17. doi: 10.1016/j.virol.2004.08.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  165. Santantonio T, Niro GA, Sinisi E, Leandro G, Insalata M, Guastadisegni A, Facciorusso D, Gravinese E, Andriulli A, Pastore G. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol. 2002;36:799–804. doi: 10.1016/S0168-8278(02)00056-9. [DOI] [PubMed] [Google Scholar]
  166. Santantonio T, Fasano M, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, Francavilla R, Pastore G. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol. 2005;42:329–333. doi: 10.1016/j.jhep.2004.11.021. [DOI] [PubMed] [Google Scholar]
  167. Saracco G, Rosina F, Brunetto MR, Amoroso P, Caredda F, Farci P, Piantino P, Bonino F, Rizzetto M. Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection. J Hepatol. 1987;5:274–281. doi: 10.1016/S0168-8278(87)80032-6. [DOI] [PubMed] [Google Scholar]
  168. Sarin SK, Kumar M, Kumar R, Kazim SN, Guptan RC, Sakhuja P, Sharma BC. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Am J Gastroenterol. 2005;100:2463–2471. doi: 10.1111/j.1572-0241.2005.00247.x. [DOI] [PubMed] [Google Scholar]
  169. Sarin SK, Sood A, Kumar M, Arora A, Amrapurkar D, Sharma BC, Konar A, Chawla YK, Jain RK, Nanda V, Kumar A, Hissar S, Lavate P, Lahoti D. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol. 2007;102:96–104. doi: 10.1111/j.1572-0241.2006.01006.x. [DOI] [PubMed] [Google Scholar]
  170. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink CJ, Reesink HW, Zeuzem S, Kwong AD. Dynamic HCV genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir (VX-950) Gastroenterology. 2007;132:1767–1777. doi: 10.1053/j.gastro.2007.02.037. [DOI] [PubMed] [Google Scholar]
  171. Scagnolari C, Vicenzi E, Bellomi F, Stillitano MG, Pinna D, Poli G, Clementi M, Dianzani F, Antonelli G. Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antivir Ther. 2004;9:1003–1011. [PubMed] [Google Scholar]
  172. Seth RB, Sun L, Chen ZJ. Antiviral innate immunity pathways. Cell Res. 2006;16:141–147. doi: 10.1038/sj.cr.7310019. [DOI] [PubMed] [Google Scholar]
  173. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003;4:63–68. doi: 10.1038/ni873. [DOI] [PubMed] [Google Scholar]
  174. Shi M, Wang RS, Zhang H, Zhu YF, Han B, Zhang Y, Jin LJ, Yang ZJ, Xu YP. Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations. J Antimicrob Chemother. 2006;58:1031–1035. doi: 10.1093/jac/dkl385. [DOI] [PubMed] [Google Scholar]
  175. Shiratori Y, Nakata R, Shimizu N, Katada H, Hisamitsu S, Yasuda E, Matsumura M, Narita T, Kawada K, Omata M. High viral eradication with a daily 12-week natural interferon-beta treatment regimen in chronic hepatitis C patients with low viral load. Dig Dis Sci. 2000;45:2414–2421. doi: 10.1023/A:1005655428563. [DOI] [PubMed] [Google Scholar]
  176. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 1972;177:705–706. doi: 10.1126/science.177.4050.705. [DOI] [PubMed] [Google Scholar]
  177. Sjogren MH, Sjogren R, Jr, Lyons MF, Ryan M, Santoro J, Smith C, Reddy KR, Bonkovsky H, Huntley B, Faris-Young S. Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin. Dig Dis Sci. 2007;52:1540–1547. doi: 10.1007/s10620-007-9757-9. [DOI] [PubMed] [Google Scholar]
  178. Snoeck E, Wade JR, Duff F, Lamb M, Jorga K. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br J Clin Pharmacol. 2006;62:699–709. doi: 10.1111/j.1365-2125.2006.02741.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  179. Solis M, Goubau D, Romieu-Mourez R, Genin P, Civas A, Hiscott J. Distinct functions of IRF-3 and IRF-7 in IFN-alpha gene regulation and control of anti-tumor activity in primary macrophages. Biochem Pharmacol. 2006;72:1469–1476. doi: 10.1016/j.bcp.2006.06.002. [DOI] [PubMed] [Google Scholar]
  180. Solomon T, Dung NM, Wills B, Kneen R, Gainsborough M, Diet TV, Thuy TT, Loan HT, Khanh VC, Vaughn DW, White NJ, Farrar JJ. Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet. 2003;361:821–826. doi: 10.1016/S0140-6736(03)12709-2. [DOI] [PubMed] [Google Scholar]
  181. Soza A, Heller T, Ghany M, Lutchman G, Jake Liang T, Germain J, Hsu HH, Park Y, Hoofnagle JH. Pilot study of interferon gamma for chronic hepatitis C. J Hepatol. 2005;43:67–71. doi: 10.1016/j.jhep.2005.02.023. [DOI] [PubMed] [Google Scholar]
  182. Swain MG, Lai MY, Shiffman ML, Cooksley WGE, Abergel A, Lin A, Connell E, Diago M. Durable sustained virological response after treatment with peginterferon alfa-2a (Pegasys) alone or in combination with ribavirin (Copegus): 5-year follow-up and the criteria for a cure. J Hepatol. 2007;46(1):S3. doi: 10.1016/S0168-8278(07)61599-2. [DOI] [Google Scholar]
  183. Takaoka A, Yanai H. Interferon signalling network in innate defence. Cell Microbiol. 2006;8:907–922. doi: 10.1111/j.1462-5822.2006.00716.x. [DOI] [PubMed] [Google Scholar]
  184. Uematsu S, Akria S. Toll-like receptors and type I interferons. J Biol Chem. 2007;282:15319–15323. doi: 10.1074/jbc.R700009200. [DOI] [PubMed] [Google Scholar]
  185. Uze G, Monneron D. IL-28 and IL-29: newcomers to the interferon family. Biochimie. 2007;89:729–734. doi: 10.1016/j.biochi.2007.01.008. [DOI] [PubMed] [Google Scholar]
  186. van der Ende M, Mulder JW, van den Berge M, Blok W, Schutten M. Complete clinical and virological remission of refractory HIV-related Kaposi's sarcoma with pegylated interferon alpha. AIDS. 2007;21:1661–1662. doi: 10.1097/QAD.0b013e32827035a4. [DOI] [PubMed] [Google Scholar]
  187. van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Murad SD, de Man RA, Schalm SW, Janssen HL. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology. 2004;39:804–810. doi: 10.1002/hep.20128. [DOI] [PubMed] [Google Scholar]
  188. van Zonneveld M, Zondervan PE, Cakaloglu Y, Simon C, Akarca US, So TM, Flink HJ, de Man RA, Schalm SW, Janssen HL. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine. Liver Int. 2006;26:399–405. doi: 10.1111/j.1478-3231.2006.01257.x. [DOI] [PubMed] [Google Scholar]
  189. Vassiliadis T, Tziomalos K, Patsiaoura K, Zagris T, Giouleme O, Soufleris K, Grammatikos N, Theodoropoulos K, Mpoumponaris A, Dona K, Zezos P, Nikolaidis N, Orfanou-Koumerkeridou E, Balaska A, Eugenidis N. Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B. J Gastroenterol Hepatol. 2007;22:1582–1588. doi: 10.1111/j.1440-1746.2007.05103.x. [DOI] [PubMed] [Google Scholar]
  190. Villa E, Trande P, Grottola A, Buttafoco P, Rebecchi AM, Stroffolini T, Callea F, Merighi A, Camellini L, Zoboli P, Cosenza R, Miglioli L, Loria P, Iori R, Carulli N, Manenti F. Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study. Dig Dis Sci. 1996;41:1241–1247. doi: 10.1007/BF02088244. [DOI] [PubMed] [Google Scholar]
  191. Villano SA, Raible D, Harper D, Speth J, Chandra P, Shaw P, Bichier G. Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with pagylated interferon alfa-2b in treatment-naive patients with chronic HCV. J Hepatol. 2007;46:S24. doi: 10.1016/S0168-8278(07)61648-1. [DOI] [Google Scholar]
  192. Wang T, Blatt LM, Seiwert SD. Immunomodulatory activities of IFN-gamma1b in combination with type I IFN: implications for the use of IFN-gamma1b in the treatment of chronic HCV infections. J Interferon Cytokine Res. 2006;26:473–483. doi: 10.1089/jir.2006.26.473. [DOI] [PubMed] [Google Scholar]
  193. Weng HL, Wang BE, Jia JD, Wu WF, Xian JZ, Mertens PR, Cai WM, Dooley S. Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study. Clin Gastroenterol Hepatol. 2005;3:819–828. doi: 10.1016/S1542-3565(05)00404-0. [DOI] [PubMed] [Google Scholar]
  194. Wheelock EF, Sibley WA. Circulating virus, interferon and antibody after vaccination with the 17-D strain of yellow-fever virus. N Engl J Med. 1965;273:194–198. doi: 10.1056/NEJM196507222730404. [DOI] [PubMed] [Google Scholar]
  195. Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, Kauffmann W, Kallinowski B, Cornberg M, Jaeckel E, Wedemeyer H, Manns MP. Early monotherapy with pegy-lated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology. 2006;43:250–256. doi: 10.1002/hep.21043. [DOI] [PubMed] [Google Scholar]
  196. Wolters LM, van Nunen AB, Honkoop P, Vossen AC, Niesters HG, Zondervan PE, de Man RA. Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat. 2000;7:428–434. doi: 10.1046/j.1365-2893.2000.00254.x. [DOI] [PubMed] [Google Scholar]
  197. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993;119:312–323. doi: 10.7326/0003-4819-119-4-199308150-00011. [DOI] [PubMed] [Google Scholar]
  198. Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M, Fischer C, Currie G, Brosgart C, Petersen J. Pegin-terferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006;44:675–684. doi: 10.1002/hep.21282. [DOI] [PubMed] [Google Scholar]
  199. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, Fujita T. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol. 2004;5:730–737. doi: 10.1038/ni1087. [DOI] [PubMed] [Google Scholar]
  200. Yurdaydin C, Bozkaya H, Cetinkaya H, Sahin T, Karaoguz D, Toruner M, Erkan O, Heper AO, Erden E, Bozdayi AM, Uzunalimoglu O. Lamivudine vs lamivudine and interferon combination treatment of HBeAg(−) chronic hepatitis B. J Viral Hepat. 2005;12:262–268. doi: 10.1111/j.1365-2893.2005.00566.x. [DOI] [PubMed] [Google Scholar]
  201. Yurdaydin C, Wedemeyer H, Dalekos G, Erhardt A, Cakaloglu Y, Degertekin H, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Dienes HP, Bock T, Manns MP. A multicenter randomized study comparing the efficacy of pegylated interferon-alpha-2a plus adefovir dipivoxil versus pegyated interferon-alpha-2a plus placebo versus adefovir dipivoxil for the treatment of chronic hepatitis delta hepatitis: the HEP-NET/International Delta Hepatitis Intervention Trial (HID-IT) Hepatology. 2006;44:230A. [Google Scholar]
  202. Zeuzem S, Benhamou Y, Bain V, Shouval D, Pianko S, Flisiak R, Grigorescu M, Rehak V, Yoshida E, Kaita K, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG. Antiviral response at week 12 following completion of treatment with Albinterferon alpha-2b plus ribavirin in genotype 1, IFN-naive, chronic hepatitis patients. J Hepatol. 2007;46:S293. doi: 10.1016/S0168-8278(07)62377-0. [DOI] [Google Scholar]
  203. Zhao H, Kurbanov F, Wan MB, Yin YK, Niu JQ, Hou JL, Wei L, Wang GQ, Tanaka Y, Mizokami M, Si CW. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis. 2007;44:541–548. doi: 10.1086/511042. [DOI] [PubMed] [Google Scholar]

Articles from Antiviral Strategies are provided here courtesy of Nature Publishing Group

RESOURCES